Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
May 05 2024 - 8:00AM
Business Wire
- SIGNA MAGNUSi is a high-performance head-only MR scanner from
GE HealthCare that could expand the field of neuroscience, which
has been limited by the performance of conventional whole-body MR
systems thus far.
- This system is designed to advance MR research in complex
imaging procedures in neurology, oncology & psychiatry.
GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA MAGNUS, an FDA
510(k) pending head-only magnetic resonance (MR) scanner designed
to explore advancements in neuroscience, which have been restricted
by the performance limitations of conventional whole-body MR
systems. Neuroscience, particularly in the study of psychiatric
diseases and neurological disorders such as Alzheimer’s, has been
constrained by technological and biological limitations, leaving
many aspects of the brain structure and functionality largely
unexplored.
Today, 43% of the world’s population suffer from neurological
disordersii, yet only a fraction can be diagnosed by MRI, making
the need to expand the neurological clinical applications of MRI
critical. SIGNA MAGNUS represents GE HealthCare’s vision of our
most advanced 3.0T MR imaging device, specifically designed for the
highest standards of neurological and oncological research for
head-only imaging. SIGNA MAGNUS stands at the pinnacle of MR
excellence, designed to offer detail and clarity that allows for an
in-depth exploration of brain microstructure, microvasculature, and
function. Through SIGNA MAGNUS, GE HealthCare will help to empower
neuroscientists, neurologists, neuroradiologists and oncologists to
transcend barriers, with the goal of enhancing the diagnosis,
understanding, and treatment of complex diseases.
"With SIGNA MAGNUS, we are not just exploring the possibility of
providing the tool; we are setting new benchmarks in medical
research and future clinical patient care,” said Kelly Londy, CEO,
MR GE HealthCare.
“This innovation underscores our commitment to R&D and our
collaborations with academia, pushing the boundaries of what's
possible in MR imaging. The potential impact of SIGNA MAGNUS on
patient outcomes and our understanding of the human brain is
profound."
This advanced system offers superior gradient performance with
its HyperG gradient technology, featuring 300 mT/m and 750 T/m/s,
enabling the detection of fine details that were previously
unattainable. Researchers can fully utilize SIGNA MAGNUS
capabilities to push the boundaries of advanced anatomical,
diffusion and functional techniques, amplified by the latest
deep-learning algorithms that GE HealthCare has to offer. SIGNA
MAGNUS is designed to be a gateway to new research opportunities,
helping to uncover new parameters and biomarkers with its vast
potential. Its innovative asymmetric gradient design allows for
remarkable diffusion performance, achieving extremely high B-value
diffusion with short echo times (TEs), which further refines the
understanding of neural architecture. Additionally, many GE
HealthCare 3.0T systems are upgradable to SIGNA MAGNUS, which will
help potential customers to save on capital costs.
In March 2024, the investigational MAGNUS system was
successfully installed at Brigham and Women’s Hospital, a leading
research institution. The Brigham team will play a crucial
collaborative role in performing research on high-performance neuro
MR with GE HealthCare. “With this system, we will be able to
measure things that weren’t possible with conventional MRI,” said
Carl-Fredrik Westin, PhD, the project’s principal investigator, who
is also founding director of the Laboratory of Mathematics in
Imaging and director of the Neuroimaging Analysis Center in the
Department of Radiology. “We can ask questions we couldn’t ask
before.”
By fostering a rich environment of innovation and collaboration,
GE HealthCare continues to lead in transforming the landscape of
medical research and healthcare delivery, with the aim of ensuring
that every scientific advancement translates into meaningful health
outcomes for patients worldwide.
Learn more about SIGNA MAGNUS at the International Society for
Magnetic Resonance in Medicine (ISMRM) Annual Meeting, taking place
from May 4-9, 2024, in Singapore, or online here:
gehealthcare.com.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), Facebook,
Instagram, and Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
_______________ i 510(k) Pending at FDA. Not Available for Sale
in the United States. Not yet CE marked. Cannot be placed on the
market or put into service until it has been made to comply with CE
marking. Not cleared or approved by any global regulator for
commercial availability. ii Global, regional, and national burden
of disorders affecting the nervous system, 1990–2021: a systematic
analysis for the Global Burden of Disease Study 2021.
LancetNeurol2024; 23: 344–81 Huang Y, Li YA, Pan HY, Han LY.
Global, regional, and national burden of neurological disorders in
204 countries and territories worldwide. J Glob Health
2023;13:04160.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240505668330/en/
GE HealthCare Media Contact: Maureen Oladipo +1 229 418
4479 maureen.oladipo@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From May 2024 to Jun 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jun 2023 to Jun 2024